

Serial No.10/826,901

Listing of Claims:

Claim 1 (previously presented) The method of treating Familian Mediterranean Fever (FMF) in a patient suffering only from FMF, which consists of orally administering, on an average daily basis, between 5 and 15 milligrams of leukotriene receptor antagonist (LTRA) selected from the group consisting of 4-5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl-3-methoxy-N-o-tonylsulfanylbenzamide and montelukant sodium to said patient and continuing said administration at said milligram level, and said average daily basis level as long as the FMF symptoms continue.

Claim 2 (cancelled)

Serial No.10/826,901

Claim 3 (currently amended) The method of claim 1 wherein said LTRA is administered orally in tablet form, wherein about 10 milligrams of said LTRA is administered, on a daily basis, for periods of time varying from 5 months to 2 ½ years and wherein said LTRA consists of ZAFIRLUCAST tablets.

Claim 4 (currency amended) The method of claim 1 wherein said LTRA is administered orally in tablet form, wherein about 10 milligrams of said LTRA is administered, on a daily basis, for periods of time varying from 5 months to 2 ½ years and wherein said LTRA consists of SINGULAIR tablets.

Claim 5 (previously presented) The method of claim 1 wherein said patient is between 9 and 72 years old.

Claim 6 (cancelled)

Claim 7 (cancelled)